ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.17%
US Dollar vs MXN
16.6201
0.39%
Brent Oil
82.445
-1.30%
Bitcoin
70,086.74
-1.91%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Royalty Pharma PLC (RPRX)

  7. Royalty Pharma PLC (RPRX) Noticias

RPRX

Royalty Pharma (RPRX)

Royalty Pharma PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RPRX
FechaHoraFuenteTítuloSímboloCompañía
16/05/202416:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RPRXRoyalty Pharma PLC
13/05/202407:15GlobeNewswire Inc.Royalty Pharma to Present at Upcoming Investor ConferencesNASDAQ:RPRXRoyalty Pharma PLC
09/05/202408:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RPRXRoyalty Pharma PLC
09/05/202406:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
09/05/202406:00GlobeNewswire Inc.Royalty Pharma Reports First Quarter 2024 ResultsNASDAQ:RPRXRoyalty Pharma PLC
09/05/202405:45GlobeNewswire Inc.Royalty Pharma to Acquire Royalty Interest in Sanofi’s FrexalimabNASDAQ:RPRXRoyalty Pharma PLC
19/04/202407:15GlobeNewswire Inc.Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024NASDAQ:RPRXRoyalty Pharma PLC
17/04/202407:15GlobeNewswire Inc.Royalty Pharma Declares Second Quarter 2024 DividendNASDAQ:RPRXRoyalty Pharma PLC
28/02/202415:15GlobeNewswire Inc.Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:RPRXRoyalty Pharma PLC
15/02/202408:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RPRXRoyalty Pharma PLC
15/02/202406:30GlobeNewswire Inc.Royalty Pharma Reports Q4 and Full Year 2023 ResultsNASDAQ:RPRXRoyalty Pharma PLC
30/01/202415:15GlobeNewswire Inc.Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024NASDAQ:RPRXRoyalty Pharma PLC
19/01/202407:15GlobeNewswire Inc.Royalty Pharma Announces Dividend IncreaseNASDAQ:RPRXRoyalty Pharma PLC
08/01/202406:00GlobeNewswire Inc.Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
03/01/202415:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RPRXRoyalty Pharma PLC
27/11/202315:15GlobeNewswire Inc.Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:RPRXRoyalty Pharma PLC
16/11/202316:13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RPRXRoyalty Pharma PLC
13/11/202307:10GlobeNewswire Inc.Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai ProgramNASDAQ:RPRXRoyalty Pharma PLC
13/11/202307:00Business WireTeva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI ProgramNASDAQ:RPRXRoyalty Pharma PLC
08/11/202306:00GlobeNewswire Inc.Royalty Pharma Reports Third Quarter 2023 ResultsNASDAQ:RPRXRoyalty Pharma PLC
19/10/202306:59GlobeNewswire Inc.Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on EvrysdiNASDAQ:RPRXRoyalty Pharma PLC
16/10/202315:15GlobeNewswire Inc.Royalty Pharma Declares Fourth Quarter 2023 DividendNASDAQ:RPRXRoyalty Pharma PLC
11/10/202315:15GlobeNewswire Inc.Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023NASDAQ:RPRXRoyalty Pharma PLC
21/09/202307:25GlobeNewswire Inc.Royalty Pharma Appoints Eric Schneider as Chief Technology OfficerNASDAQ:RPRXRoyalty Pharma PLC
05/09/202315:15GlobeNewswire Inc.Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementNASDAQ:RPRXRoyalty Pharma PLC
05/09/202315:01GlobeNewswire Inc.Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementNASDAQ:RPRXRoyalty Pharma PLC
24/08/202305:30GlobeNewswire Inc.Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)NASDAQ:RPRXRoyalty Pharma PLC
24/08/202300:15Business WireRoyalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)NASDAQ:RPRXRoyalty Pharma PLC
08/08/202306:00GlobeNewswire Inc.Royalty Pharma Reports Second Quarter 2023 ResultsNASDAQ:RPRXRoyalty Pharma PLC
18/07/202315:15GlobeNewswire Inc.Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023NASDAQ:RPRXRoyalty Pharma PLC
 Showing the most relevant articles for your search:NASDAQ:RPRX

Su Consulta Reciente

AMEX
IIGD
Invesco Investment Grade...
USOTC
DODXF
DB AG London Lkd to DJ H... (CE)
DBI
V1H3
VDAX NEW AUGUST YYY3
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados